TPST's Lincoln Park Equity Line Covers 119% of Its Entire Public Float

With shares outstanding up 272% in twelve months and a floating-discount facility pricing off recent lows, Tempest Therapeutics carries an Elevated dilution risk grade of 7 out of 10.